Piperacillin/tazobactam vs. piperacillin/sulbactam;Piperacillin/tazobactam und piperacillin/sulbactam

Krankenhauspharmazie

Volumn 26, Issue 3, 2005, Pages 79-86

  Heizmann, Wolfgang R ^a,b   Derendorf, Hartmut ^a,c  

^a Zentrum Mikrobiol und Infektiologie ^*

^b Zentrum für Mikrobiologie und Infektiologie   (Germany)

^c UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

Comparison; Efficacy; Piperacillin; Sulbactam; Tazobactam

Indexed keywords

BETA LACTAM ANTIBIOTIC; CEFTAZIDIME; PIPERACILLIN; PIPERACILLIN PLUS SULBACTAM; PIPERACILLIN PLUS TAZOBACTAM; SULBACTAM; UNCLASSIFIED DRUG;

ABDOMINAL INFECTION; ANTIBIOTIC THERAPY; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; GERMANY; HOSPITAL INFECTION; HUMAN; INFECTION; NEUTROPENIA; PNEUMONIA; PYREXIA IDIOPATHICA; REVIEW;

EID: 16344371800     PISSN: 01737597     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. Alvarez-Lerma F. Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. ICU-acquired pneumonia study group. Intensive Care Med 1996;22:387-94.
2. Alvarez-Lerma F, Insausti-Ordenana J, Jorda-Marcos R, Maravi-Poma E, et al., Spanish collaborative group for the study of severe infections. Efficacy and tolerability of piperacillin/tazobactam versus ceftazidime in association with amikacin for treating nosocomial pneumonia in intensive care patients: a prospective randomized multicenter trial. Intensive Care Med 2001;27:493-502.
3. Bantar C, Vesco E, Heft C, Salamone F, et al. Replacement of broad-spectrum cephalosporins by piperacillin-tazobactam: impact on sustained high rates of bacterial resistance. Antimicrob Agents Chemother 2004;48: 392-5.
4. Bauduer F, Cousin T, Boulat O, Rigal-Huguet F, et al., BGMT collaborative group. A randomized prospective multicenter trial of cefpirome versus piperacillin-tazobactam in febrile neutropenia. Leuk Lymphoma 2001;42:379-86.
5. Blum RA, Kohli RK, Harrison NJ, Schentag JJ. Pharmacokinetics of ampicillin (2.0 g) and sulbactam (1.0 g) coadministered to subjects with normal and abnormal renal function and with end-stage renal disease on hemodialysis. Antimicrob Agents Chemother 1989;33: 1470-6.
6. Böhme A, Shah PM, Stille W, Hoelzer D. Piperacillin/tazobactam versus cefepime as initial empirical antimicrobial therapy in febrile neutropenic patients: a prospective randomized pilot study. Eur J Med Res 1998;20: 324-30.
7. Bourget P, Lesne-Hulin A, Le Reveille R, Le Bever H, et al. Clinical pharmacokinetics of piperacillin-tazobactam combination in patients with major burns and signs of infection. Antimicrob Agents Chemother 1996;40: 139-45.
8. Brismar B, Malmborg AS, Tunevall G, Wretlind B, et al. Piperacillin-tazobactam versus imipenem-cilastatin for treatment of intra-abdominal infections. Antimicrob Agents Chemother 1992;36:2766-73.
9. Brown RM, Wise R, Andrews JM, Hancox J. Comparative pharmacokinetics and tissue penetration of sulbactam and ampicillin after concurrent intravenous administration. Antimicrob Agents Chemother 1982;21: 565-7.
10. Brun-Buisson C, Sollet JP, Schweich H, Briere S, et al. Treatment of ventilator-associated pneumonia with piperacillin-tazobactam/ amikacin versus ceftazidime/amikacin: a multicenter, randomized controlled trial. VAP study group. Clin Infect Dis 1998;26:346-54.
11. Bryson HM, Brogden RN. Piperacillin/ tazobactam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential. Drugs 1994;47:506-35.
12. Cometta A, Zinner S, de Bock R, Calandra T, et al. Piperacillin- tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The international antimicrobial therapy cooperative group of the European organization for research and treatment of cancer. Antimicrob Agents Chemother 1995;39:445-52.
13. Craig WA. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis 1995;22:89-96.
14. Dalla Costa T, Nolting A, Rand K, Derendorf H. Pharmacokinetic- pharmacodynamic modelling of the in vitro antiinfective effect of piperacillin-tazobactam combinations. Int J Clin Pharmacol Ther 1997;35:426-33.
15. De la Pena A, Derendorf H. Pharmacokinetic properties of beta-lactamase inhibitors. Int J Clin Pharmacol Ther 1999;37:63-75.
16. De la Pena A, Graebe A, Derendorf H. Pharmakokinetik von Beta-Lactamase-Inhibitoren bei eingeschränkter Nierenfunktion. Chemotherapie J 2000;9:107-13.
17. Del Favero A, Menichetti F, Martino P, Bucaneve G, et al., gruppo italiano malattie ematologiche dell'adulto (GIMEMA) infection program. A multicenter, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia. Clin Infect Dis 2001;33:1295-301.
18. Derendorf H, Dalla Costa T. Pharmacokinetics of piperacillin, tazobactam and its metabolite in renal impairment. Int J Clin Pharmacol Ther 1996;34:482-8.
19. Dupont H, Carbon C, Carlet J. Monotherapy with a broad-spectrum beta-lactam is as effective as its combination with an aminoglycoside in treatment of severe generalized peritonitis: a multicenter randomized controlled trial. The severe generalized peritonitis study group. Antimicrob Agents Chemother 2000;44:2028-33.
20. Figuera A, Rivero N, Pajuelo F, Font P, et al. Comparative study of piperacillin/tazobactam versus imipenem/cilastatin in febrile neutropenia (1994-1996). Med Clin (Barc) 2001; 116: 610-1.
21. Fleischhack G, Schmidt-Niemann M, Wulff B, Havers W, et al. Piperacillin, beta-lactam inhibitor plus gentamicin as empirical therapy of a sequential regimen in febrile neutropenia of pediatric cancer patients. Support Care Cancer 2001;9:372-9.
22. Foulds G, Knirsch AK, Stankewich JP, Weidler DR. The parenteral kinetics of ampicillin/ sulbactam in man. Int J Clin Pharmacol Res 1985;5:79-86.
23. Foulds G, Miller RD, Knirsch AK, Thrupp LD. Sulbactam kinetics and excretion into breast milk in postpartum women. Clin Pharmacol Ther 1985;38:692-6.
24. Foulds G. Pharmacokinetics of sulbactam/ ampicillin in humans: a review. Rev Infect Dis 1986;8(Suppl 5):S503-11.
25. Fowler RA, Flavin KE, Barr J, Weinacker AB, et al. Variability in antibiotic prescribing patterns and outcomes in patients with clinically suspected ventilator-associated pneumonia. Chest 2003;123:835-44.
26. Frank U, Mutter J, Schmidt-Eisenlohr E, Daschner FD. Comparative in vitro activity of piperacillin, piperacillin-sulbactam and piperacillin-tazobactam against nosocomial pathogens isolated from intensive care patients. Clin Microbiol Infect 2003;9: 1128-32.
27. Gesser RM, McCarroll K, Teppler H, Woods GL. Efficacy of ertapenem in the treatment of serious infections caused by enterobacteriaceae: analysis of pooled clinical trial data. J Antimicrob Chemother 2003;51:1253-60.
28. Gorschluter M, Hahn C, Fixson A, Mey U, et al. Piperacillin-tazobactam is more effective than ceftriaxone plus gentamicin in febrile neutropenic patients with hematological malignancies: a randomized comparison. Support Care Cancer 2003;11:362-70.
29. Grimm H, Blessing J, Funke G. In-vitro-Aktivität von Piperacillin in Kombination mit Tazobactam sowie mit Sulbactam gegen Piperacillin-nicht- sensible Enterobacteriaceae. Chemother J 2003;12:174-7.
30. Halstenson CE. Pharmacokinetics of tazobactam M1 metabolite after administration of piperacillin/tazobactam in subjects with renal impairment. J Clin Pharmacol 1994;34: 1208-17.
31. Hazel DL, Graham J, Dickinson JP, Newland AC, et al. Piperacillin- tazobactam as empiric monotherapy in febrile neutropenic patients with haematological malignancies. J Chemother 1997;9:267-72.
32. Hess U, Böhme C, Rey K, Senn HJ. Monotherapy with piperacillin/tazobactam versus combination therapy with ceftazidime plus amikacin as an empiric therapy for fever in neutropenic cancer patients. Support Care Cancer 1998;6:402-9.
33. Ibrahim EH, Sherman G, Ward S, Fraser VJ, et al. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000;118: 146-55.
34. Jaccard C, Troillet N, Harbarth S, Zanetti G, et al. Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis. Antimicrob Agents Chemother 1998;42: 2966-72.
35. Jhee SS, Kern JW, Burm JP, Yellin AE, et al. Piperacillin-tazobactam pharmacokinetics in patients with intraabdominal infections. Pharmacotherapy 1995;15:472-8.
36. Johnson CA, Halstenson CE, Kelloway JS, Shapiro BE, et al. Single-dose pharmacokinetics of piperacillin and tazobactam in patients with renal disease. Clin Pharmacol Ther 1992;51:32-41.
37. Joshi M, Bernstein J, Solomkin J, Wester BA, et al. Piperacillin/ tazobactam plus tobramycin versus ceftazidime plus tobramycin for the treatment of patients with nosocomial lower respiratory tract infection. Piperacillin/ tazobactam nosocomial pneumonia study group. J Antimicrob Chemother 1999;43: 389-97.
38. Kuck NA, Jacobus NV, Petersen PJ, Weiss WJ, et al. Comparative in vitro and in vivo activities of piperacillin combined with the beta-lactamase inhibitors tazobactam, clavulanic acid, and sulbactam. Antimicrob Agents Chemother 1989;33:1964-9.
39. Leibovici L, Shraga I, Drucker M, Konigsberger H, et al. The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection. J Intern Med 1998;244: 379-86.
40. Lister PD, Prevan AM, Sanders CC. Importance of beta-lactamase inhibitor pharmacokinetics in the pharmacodynamics of inhibitor-drug combinations: studies with piperacillin-tazobactam and piperacillin-sulbactam. Antimicrob Agents Chemother 1997;41:721-7.
41. Liu Q, Rand K, Derendorf H. Impact of tazobactam pharmacokinetics on the antimicrobial effect of piperacillin-tazobactam combinations. Int J Antimicrob Agents 2004;23: 494-7.
42. Luna CM, Vujacich P, Niederman MS, Vay C, et al. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest 1997;111:676-85.
43. Manncke K, Springsklee M, Heizmann WR, Sonntag HG. Sulbactam in combination with mezlocillin, piperacillin or cefotaxime. Clinical and bacteriological results in the treatment of severe bacterial infections. Med Klin 1991;86:454-60.
44. Marie JP, Vekhoff A, Cony-Makhoul P, Fiere D, et al. Piperacilline/ tazobactam combination + amikacin versus ceftazidime + amikacin in patients with neutropenia and fever. An open multicenter study. Groupe d'étude des aplasies febriles. Presse Med 1995;24: 397-401.
45. Marie JP, Marjanovic Z, Vekhoff A, Bouvet A, et al. Piperacillin/ tazobactam plus tobramycin versus ceftazidime plus tobramycin as empiric therapy for fever in severely neutropenic patients. Support Care Cancer 1999;7:89-94.
46. Mouton Y, Leroy O, Beuscart C, Chidiac C, et al. Efficacy, safety and tolerance of parenteral piperacillin/tazobactam in the treatment of patients with lower respiratory tract infections. J Antimicrob Chemother 1993;31(Suppl A): 87-95.
47. Niinikoski J, Havia T, Alhava E, Paakkonen M, et al. Piperacillin/ tazobactam versus imipenem/cilastatin in the treatment of intra-abdominal infections. Surg Gynecol Obstet 1993;176:255-61.
48. Occhipinti DJ, Pendland SL, Schoonover LL, Rypins EB, et al. Pharmacokinetics and pharmacodynamics of two multiple-dose piperacillin- tazobactam regimens. Antimicrob Agents Chemother 1997;41:2511-7.
49. Ohlin B, Cederberg A, Forssell H, Solhaug JH, et al. Piperacillin/ tazobactam compared with cefuroxime/metronidazole in the treatment of intra-abdominal infections. Eur J Surg 1999;165:875-84.
50. Payne DJ, Cramp R, Winstanley DJ, Knowles DJ. Comparative activities of clavulanic acid, sulbactam, and tazobactam against clinically important beta-lactamases. Antimicrob Agents Chemother 1994;38:767-72.
51. Reed MD, Goldfarb J, Yamashita TS, Lemon E, et al. Single-dose pharmacokinetics of piperacillin and tazobactam in infants and children. Antimicrob Agents Chemother 1994;38: 2817-26.
52. Reitberg DP, Marble DA, Schultz RW, Whall TJ, et al. Pharmacokinetics of cefoperazone (2.0 g) and sulbactam (1.0 g) coadministered to subjects with normal renal function, patients with decreased renal function, and patients with end-stage renal disease on hemodialysis. Antimicrob Agents Chemother 1988;32:503-9.
53. Rello J, Gallego M, Mariscal D, Sonora R, et al. The value of routine microbial investigation in ventilator-associated pneumonia. Am J Respir Crit Care Med 1997;156:196-200.
54. Ripa S, Ferrante L, Prenna M. Pharmacokinetics of sulbactam/ampicillin in humans after intravenous and intramuscular injection. Chemotherapy 1990;36:185-92.
55. Rodloff AC, Pleß B, Beer J, Spencker F-B. In-vitro-Aktivität von Piperacillin/Sulbactam und Piperacillin/Tazobactam. Chemother J 2001;10:181-7.
56. Sanz MA, Lopez J, Lahuerta JJ, Rovira M, et al., Spanish PETHEMA group. Cefepime plus amikacin versus piperacillin-tazobactam plus amikacin for initial antibiotic therapy in haematology patients with febrile neutropenia: results of an open, randomized, multicenter trial. J Antimicrob Chemother 2002;50:79-88.
57. Sörgel F, Kinzig M. The chemistry, pharmacokinetics and tissue distribution of piperacillin/tazobactam. J Antimicrob Chemother 1993;31(Suppl A):39-60.
58. Solomkin JS, Yellin AE, Rotstein OD, Christou NV, et al., protocol 017 study group. Ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections: results of a double-blind, randomized comparative phase III trial. Ann Surg 2003;237:235-45.
59. Stewart M, Taylor EW, Lindsay G. Infection after colorectal surgery: a randomized trial of prophylaxis with piperacillin versus sulbactam/piperacillin. West of Scotland surgical infection study group. J Hosp Infect 1995;29:135-42.
60. Valtonen M, Tiula E, Takkunen O, Backman JT, et al. Elimination of the piperacillin/ tazobactam combination during continuous venovenous haemofiltration and haemodia-filtration in patients with acute renal failure. J Antimicrob Chemother 2001;48:881-5.
61. Westphal JF, Brogard JM, Caro-Sampara F, Adloff M, et al. Assessment of biliary excretion of piperacillin-tazobactam in humans. Antimicrob Agents Chemother 1997;41: 1636-40.
62. Westphal K, Weigand I, Pfeil E, Krüpe H, et al. Nicht nur ESBL produzierende E.-coli-Stämme bereiten therapeutische Probleme - ein Fallbericht. Chemother J 2000;9:153-4.
63. Wildfeuer A, Schmalreck A, Räder K, Eibel G, et al. Studies on the synergism of sulbactam and beta-lactam antibiotics under in vitro conditions and in healthy volunteers after intravenous administration. Antibacterial activity in vitro, compatibility and pharmacokinetics of the drugs in combination. Arzneimittelforschung/Drug Res 1989;39:94-100.